本ガイドラインにおける略語一覧

(アルファベット順)

略 語 説 明
AFIP Armed Forces Institute of Pathology
AGITG Australasian Gastro-Intestinal Trials Group
ASCO American Society of Clinical Oncology
CR complete response
CT computed tomography
ECOG Eastern Cooperative Oncology Group
EORTC European Organization for Research and Treatment of Cancer
ESD endoscopic submucosal dissection
ESMO European Society of Medical Oncology
EUS endoscopic ultrasonography
EUS-FNAB endoscopic ultrasonography guided fine needle aspiration biopsy
FDA Food and Drug Administration
HE hematoxylin and eosin
HPF high power field
HR hazard ratio
IC informed consent
IFP inflammatory fibroid polyp
IGF1R insulin-like growth factor 1 receptor
ISG Italian Sarcoma Group
Lancet The Lancet
MDCT multidetector-row computed tomography
MRI magnetic resonance imaging
N Engl J Med The New England Journal of Medicine
NCCN National Comprehensive Cancer Network
NCI-CTCAE National Cancer Institute – Common Terminology Criteria for Adverse Events
NE not evaluable
NF1 neurofibromatosis type 1
NIH National Institutes of Health
OS overall survival
PD progressive disease
PERCIST Positron Emission tomography Response Criteria In Solid Tumor
PET/CT positron emission tomography/computed tomography
PFS progression-free survival
PNET pancreas neuroendocrine tumor
PR partial response
PS Performance Status
QOL quality of life
RECIST Response Evaluation Criteria In Solid Tumor
RFA radiofrequency ablation
RFS recurrence-free survival
ROI region of interest
RTOG Radiation Therapy Oncology Group
SD stable disease
SMT submucosal tumor
SSGXVIII Scandinavian Sarcoma Group XVIII
SUV standardized uptake value
SWOG Southwest Oncology Group
TAE transarterial embolization
18F-FDG-avid fluorine-18-fluorodeoxyglucose--avid
18F-FDG-PET又はF-18 FDG-PET fluorine-18-fluorodeoxyglucose-positron emission tomography